NCT04068753 2026-02-10
STAR
University of Oklahoma
Phase 2 Active not recruiting
Clinical Trials
13 trialsNCT06238635 2026-01-13
Dostarlimab and Cobolimab in Advanced Cervical Cancer
Beth Israel Deaconess Medical Center
Phase 2 Active not recruiting
NCT06062420 2026-01-09
A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202
GlaxoSmithKline
Phase 2 Active not recruiting
NCT05565378 2026-01-08
A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer
GlaxoSmithKline
Phase 2 Active not recruiting
NCT05723562 2026-01-08
AZUR-1
GlaxoSmithKline
Phase 2 Active not recruiting
NCT04701307 2025-12-15
Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT06640049 2025-11-17
China AZUR-1
GlaxoSmithKline
Phase 2 Active not recruiting
NCT04126200 2025-11-06
DREAMM5
GlaxoSmithKline
Phase 2 Active not recruiting
NCT04139902 2025-10-15
Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022) and PD-1 Inhibitor Dostarlimab (TSR-042) in Melanoma
University of Pittsburgh
Phase 2 Active not recruiting
NCT04584255 2025-07-28
Niraparib + Dostarlimab In BRCA Mutated Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT06317311 2025-07-25
RUBY-J
GlaxoSmithKline
Phase 2 Active not recruiting
NCT03833479 2025-05-21
ATOMICC
Grupo Español de Investigación en Cáncer de Ovario
Phase 2 Active not recruiting
NCT04313504 2024-08-01
Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Recurrent/Metastatic HNSCC
University of Cincinnati
Phase 2 Active not recruiting